▶ 調査レポート

循環腫瘍細胞(CTC)予後技術の世界市場2020年:企業別、地域別、種類・用途別

• 英文タイトル:Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。循環腫瘍細胞(CTC)予後技術の世界市場2020年:企業別、地域別、種類・用途別 / Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / MRC2012B0193資料のイメージです。• レポートコード:MRC2012B0193
• 出版社/出版日:GlobalInfoResearch / 2020年12月21日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、103ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療、製薬
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、循環腫瘍細胞(CTC)予後技術の世界市場を広く調査・分析し、今後の市場展望をまとめております。循環腫瘍細胞(CTC)予後技術の種類別市場規模(腫瘍細胞濃縮、腫瘍細胞検出)、用途別市場規模(前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):AdnaGen、Vitatex、Epic Sciences、ACDBio、Silicon Biosystems、Celula、Rarecells、Fluxion Biosciences、
・地域別グローバル市場分析 2015年-2020年
・循環腫瘍細胞(CTC)予後技術の北米市場(アメリカ、カナダ、メキシコ)
・循環腫瘍細胞(CTC)予後技術のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・循環腫瘍細胞(CTC)予後技術のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・循環腫瘍細胞(CTC)予後技術の南米市場(ブラジル、アルゼンチン)
・循環腫瘍細胞(CTC)予後技術の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:腫瘍細胞濃縮、腫瘍細胞検出
・用途別分析:前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん
・地域別市場規模予測 2021年-2025年
・調査の結果・結論

Market Overview
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 14.3% in the forecast period of 2020 to 2025 and will expected to reach USD 2270.4 million by 2025, from USD 1331.5 million in 2019.

The Circulating Tumor Cells (CTCs) Prognostic Technologies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Circulating Tumor Cells (CTCs) Prognostic Technologies market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Circulating Tumor Cells (CTCs) Prognostic Technologies market has been segmented into:
Tumor Cell Enrichment
Tumor Cell Detection

By Application, Circulating Tumor Cells (CTCs) Prognostic Technologies has been segmented into:
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market presented in the report. This section sheds light on the sales growth of different regional and country-level Circulating Tumor Cells (CTCs) Prognostic Technologies markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market.

The report offers in-depth assessment of the growth and other aspects of the Circulating Tumor Cells (CTCs) Prognostic Technologies market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share Analysis
Circulating Tumor Cells (CTCs) Prognostic Technologies competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Circulating Tumor Cells (CTCs) Prognostic Technologies sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Circulating Tumor Cells (CTCs) Prognostic Technologies sales, revenue and market share for each player covered in this report.

The major players covered in Circulating Tumor Cells (CTCs) Prognostic Technologies are:
AdnaGen
Vitatex
Epic Sciences
ACDBio
Silicon Biosystems
Celula
Rarecells
Fluxion Biosciences

レポート目次

Table of Contents

1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview
1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) Prognostic Technologies
1.2 Classification of Circulating Tumor Cells (CTCs) Prognostic Technologies by Type
1.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type in 2019
1.2.3 Tumor Cell Enrichment
1.2.4 Tumor Cell Detection
1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market by Application
1.3.1 Overview: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Ovarian Cancer
1.3.7 Pancreatic Cancer
1.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market by Regions
1.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Circulating Tumor Cells (CTCs) Prognostic Technologies (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
2 Company Profiles
2.1 AdnaGen
2.1.1 AdnaGen Details
2.1.2 AdnaGen Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AdnaGen SWOT Analysis
2.1.4 AdnaGen Product and Services
2.1.5 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.2 Vitatex
2.2.1 Vitatex Details
2.2.2 Vitatex Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Vitatex SWOT Analysis
2.2.4 Vitatex Product and Services
2.2.5 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.3 Epic Sciences
2.3.1 Epic Sciences Details
2.3.2 Epic Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Epic Sciences SWOT Analysis
2.3.4 Epic Sciences Product and Services
2.3.5 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.4 ACDBio
2.4.1 ACDBio Details
2.4.2 ACDBio Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 ACDBio SWOT Analysis
2.4.4 ACDBio Product and Services
2.4.5 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.5 Silicon Biosystems
2.5.1 Silicon Biosystems Details
2.5.2 Silicon Biosystems Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Silicon Biosystems SWOT Analysis
2.5.4 Silicon Biosystems Product and Services
2.5.5 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.6 Celula
2.6.1 Celula Details
2.6.2 Celula Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Celula SWOT Analysis
2.6.4 Celula Product and Services
2.6.5 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.7 Rarecells
2.7.1 Rarecells Details
2.7.2 Rarecells Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Rarecells SWOT Analysis
2.7.4 Rarecells Product and Services
2.7.5 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.8 Fluxion Biosciences
2.8.1 Fluxion Biosciences Details
2.8.2 Fluxion Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Fluxion Biosciences SWOT Analysis
2.8.4 Fluxion Biosciences Product and Services
2.8.5 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Circulating Tumor Cells (CTCs) Prognostic Technologies Players Market Share
3.2.2 Top 10 Circulating Tumor Cells (CTCs) Prognostic Technologies Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Market Share by Regions
4.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.5 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
5.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
5.2 USA Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5.3 Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5.4 Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
6.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
6.2 Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.3 UK Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.4 France Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.5 Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.6 Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
7.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
7.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.4 Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.5 India Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
8 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
8.1 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
8.2 Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
8.3 Argentina Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Circulating Tumor Cells (CTCs) Prognostic Technologies by Countries
9.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
9.2 Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.3 UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.4 Egypt Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.5 South Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Market Share by Type (2015-2020)
10.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Type (2019-2024)
10.3 Tumor Cell Enrichment Revenue Growth Rate (2015-2025)
10.4 Tumor Cell Detection Revenue Growth Rate (2015-2025)
11 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Segment by Application
11.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Application (2015-2020)
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Application (2019-2024)
11.3 Prostate Cancer Revenue Growth (2015-2020)
11.4 Breast Cancer Revenue Growth (2015-2020)
11.5 Colorectal Cancer Revenue Growth (2015-2020)
11.6 Lung Cancer Revenue Growth (2015-2020)
11.7 Ovarian Cancer Revenue Growth (2015-2020)
11.8 Pancreatic Cancer Revenue Growth (2015-2020)
12 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast (2021-2025)
12.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast (2021-2025)
12.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Regions (2021-2025)
12.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.6 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Circulating Tumor Cells (CTCs) Prognostic Technologies by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AdnaGen Corporate Information, Location and Competitors
Table 6. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 7. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 8. AdnaGen SWOT Analysis
Table 9. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 10. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Vitatex Corporate Information, Location and Competitors
Table 12. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 13. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2018-2019)
Table 14. Vitatex SWOT Analysis
Table 15. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 16. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Epic Sciences Corporate Information, Location and Competitors
Table 18. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 19. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 20. Epic Sciences SWOT Analysis
Table 21. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 22. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. ACDBio Corporate Information, Location and Competitors
Table 24. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 25. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 26. ACDBio SWOT Analysis
Table 27. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 28. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Silicon Biosystems Corporate Information, Location and Competitors
Table 30. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 31. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 32. Silicon Biosystems SWOT Analysis
Table 33. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 34. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Celula Corporate Information, Location and Competitors
Table 36. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 37. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 38. Celula SWOT Analysis
Table 39. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 40. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Rarecells Corporate Information, Location and Competitors
Table 42. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 43. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 44. Rarecells SWOT Analysis
Table 45. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 46. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Fluxion Biosciences Corporate Information, Location and Competitors
Table 48. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Major Business
Table 49. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Total Revenue (USD Million) (2017-2018)
Table 50. Fluxion Biosciences SWOT Analysis
Table 51. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product and Solutions
Table 52. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Players (2015-2020)
Table 54. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Players (2015-2020)
Table 55. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Regions (2015-2020)
Table 56. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Regions (2015-2020)
Table 57. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
Table 58. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Table 59. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Countries (2015-2020)
Table 60. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Countries (2015-2020)
Table 61. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
Table 62. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Table 63. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Countries (2015-2020)
Table 64. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Table 65. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) by Type (2015-2020)
Table 66. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Type (2015-2020)
Table 67. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Forecast by Type (2021-2025)
Table 68. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Application (2015-2020)
Table 69. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Application (2015-2020)
Table 70. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Forecast by Application (2021-2025)
Table 71. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Circulating Tumor Cells (CTCs) Prognostic Technologies Picture
Figure 2. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type in 2019
Figure 3. Tumor Cell Enrichment Picture
Figure 4. Tumor Cell Detection Picture
Figure 5. Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Application in 2019
Figure 6. Prostate Cancer Picture
Figure 7. Breast Cancer Picture
Figure 8. Colorectal Cancer Picture
Figure 9. Lung Cancer Picture
Figure 10. Ovarian Cancer Picture
Figure 11. Pancreatic Cancer Picture
Figure 12. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share in 2019
Figure 21. Global Top 10 Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Regions (2015-2020)
Figure 25. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Regions in 2018
Figure 26. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 27. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 29. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 31. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Figure 32. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries in 2019
Figure 33. USA Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 34. Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 36. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries in 2019
Figure 38. Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 39. UK Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 40. France Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 41. Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 42. Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries in 2019
Figure 45. China Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 46. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 47. Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 48. India Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 50. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Figure 51. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries in 2019
Figure 52. Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 57. UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
Figure 60. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Type (2015-2020)
Figure 61. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Type in 2019
Figure 62. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share Forecast by Type (2021-2025)
Figure 63. Global Tumor Cell Enrichment Revenue Growth Rate (2015-2020)
Figure 64. Global Tumor Cell Detection Revenue Growth Rate (2015-2020)
Figure 65. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Application (2015-2020)
Figure 66. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Application in 2019
Figure 67. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share Forecast by Application (2021-2025)
Figure 68. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 69. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 70. Global Colorectal Cancer Revenue Growth Rate (2015-2020)
Figure 71. Global Lung Cancer Revenue Growth Rate (2015-2020)
Figure 72. Global Ovarian Cancer Revenue Growth Rate (2015-2020)
Figure 73. Global Pancreatic Cancer Revenue Growth Rate (2015-2020)
Figure 74. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
Figure 78. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
Figure 80. South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel